Indeed, a clinical study in which anti-IL-6 drugs were administered for the purpose of treating cardiovascular disease demonstrated that biomarkers of inflammation and thrombosis were decreased in CKD patients [108]. The gene discussed is IL6; the disease is cardiovascular disorder.